Charles Geyer
查尔斯·盖耶
MD
Professor of Medicine医学教授
👥Biography 个人简介
Charles Geyer led landmark NSABP/NRG trials in HER2+ breast cancer, including NSABP B-31 which co-established trastuzumab as standard adjuvant therapy. His work on pathologic complete response as a surrogate endpoint has influenced regulatory frameworks for accelerated approvals in breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Adjuvant Trastuzumab
Co-led NSABP B-31 demonstrating adjuvant trastuzumab survival benefit in HER2+ breast cancer, pooled with NCCTG N9831 to define the modern HER2+ adjuvant treatment standard.
Pathologic Complete Response as Endpoint
Contributed to validating pCR as a surrogate endpoint for EFS and OS in HER2+ neoadjuvant breast cancer trials.
Representative Works 代表性著作
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
NEJM (2005)
NSABP B-31/NCCTG N9831 joint analysis.
Neratinib after adjuvant trastuzumab for HER2-positive breast cancer
NEJM (2016)
ExteNET trial of extended adjuvant neratinib.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 查尔斯·盖耶 的研究动态
Follow Charles Geyer's research updates
留下邮箱，当我们发布与 Charles Geyer（VCU Massey Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment